Company Filing History:
Years Active: 2025
Title: Laura Thei - Innovator in VNAR Polypeptides
Introduction
Laura Thei is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the development of VNAR polypeptides. Her innovative work focuses on creating high-affinity polypeptides that can effectively bind to human transferrin receptors.
Latest Patents
Laura Thei holds a patent for Type-II VNAR polypeptides that bind human TfR-1, along with the encoding nucleic acids and methods of use. This invention relates to a high-affinity VNAR polypeptide that is cross-reactive with primate transferrin receptors. The VNAR polypeptides were developed by screening semisynthetic VNAR phage display libraries against recombinant human TfR-1. These polypeptides can be utilized alone or as components in conjugates targeting the transferrin/transferrin receptor transport system. The invention also encompasses the use of these VNARs, their conjugates, and derivatives in diagnostic and therapeutic methods. This includes applications for diagnosing, treating, and preventing conditions where delivering biomolecules across the blood-brain barrier or other membranes is beneficial. Additionally, the VNAR polypeptide can target biological barriers such as the intestines, placenta, or aberrant cells overexpressing TfR-1, providing therapeutic benefits in treating certain cancer cells and tumors.
Career Highlights
Laura Thei is currently associated with Ossianix, Inc., where she continues to advance her research and development efforts. Her work has led to the creation of innovative solutions that have the potential to impact various medical fields.
Collaborations
Laura collaborates with notable colleagues, including Pawel Stocki and Jaroslaw Michal Szary, contributing to a dynamic research environment that fosters innovation.
Conclusion
Laura Thei's contributions to the field of VNAR polypeptides exemplify her commitment to advancing biotechnology. Her innovative patent and ongoing work at Ossianix, Inc. highlight her role as a leading inventor in this important area of research.